UNSPSC 51434605: Semotiadil fumarate

This classification denotes a calcium channel blocker with the molecular formula C29H32N2O6S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48E2Q389VX, chemically known as 2h-1,4-benzothiazin-3(4h)-one, 2-(2-(3-((2-(1,3-benzodioxol-5-yloxy)ethyl)methylamino)propoxy)-5-methoxyphenyl)-4-methyl-, (2r)-, (2e)-2-butenedioate (1:1), but more generally known as semotiadil fumarate, which bears US NIH Compound Identifier 6437846.

European Medicines Agency schedules semotiadil fumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10481MIG. Most nations, for tariff purposes, schedule semotiadil fumarate under HS 29349990. SMILES: CN1C2CCCCC2S[C@@H](C1=O)C3CC(CCC3OCCCN(C)CCOC4CCC5C(C4)OCO5)OC.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51434605 Semotiadil fumarate, a Commodity code, does not align with the pharmaceutical procurement activity state and local governments are currently soliciting. The recent opportunities posted under this code involve advanced life support medications, generic multi-source pharmaceuticals, and pharmacy benefit program infrastructure — none of which specifically reference semotiadil fumarate or its clinical use. The mismatch suggests that this code shows little relevant recent activity for the specific pharmaceutical compound it nominally describes.

State and local issuing bodies posting opportunities in this category include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 seeking advanced life support medications for Tampa Fire Rescue, with a response date of April 8, 2026 and an estimated contract value of $40,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, serving state and local government facilities across participating jurisdictions including Oregon. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to explore direct-to-manufacturer prescription programs. Geographic activity concentrates in Texas, Minnesota, Florida, and Oregon, with cooperative purchasing vehicles spanning multiple state jurisdictions. Given the mismatch between the code's stated pharmaceutical and the actual scope of recent solicitations, this code warrants careful review before pursuit.